Episode 348 (Part 1) hosts David Moatazedi (President & CEO of Evolus from California, USA).
In this podcast we cover Evolus' global vision and strategy - based on shifting from a traditional pharma model toward "performance beauty".
Our conversation with David discusses market differences by country, rapid trend cycles and the need for continuing clinical evidence. We address the drop in global HA fillers, macroeconomics, pipeline strategy and future modalities.
00:00 Aesthetics Industry Shift Ahead
00:52 Show Introduction and Two-Part Format
02:14 Meet David and the Evolus Story
03:35 Evolus' North Star for Growth
05:08 Beauty Lens vs Medical Risk
08:34 How the Industry Is Maturing Worldwide
10:36 Hype Cycles and Long-Term Staying Power
13:56 The "Natural Look" and Trend Drivers
17:37 Why Evolus Went Public
19:34 Macro Risks and Pipeline Bets
22:21 The Future of HA Fillers
22:48 Why HA Fillers Have Slowed Down
24:12 Rebranding the Filler Category
26:22 Staying Customer-Centric
28:53 The Next Waves of Innovation
31:49 Robots and AI Injectors
33:05 Helping Clinics Grow
37:31 Launching in Australia
38:45 What Aesthetics Could Look Like in 2035
41:33 Pipeline Updates and New HA Technology
43:07 Wrap-Up and Where to Watch
Part 2 will be available on our new app IA Community for free very soon!
DOWNLOAD OUR NEW APP IA COMMUNITY:
